CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Author's Avatar
May 08, 2023
  • Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates
  • Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains